DEA Increases Production Quotas for Cannabis, Psilocybin, and DMT to Boost Therapeutic Research

1w
3m read
Summary

To accommodate the growing demand for research into the therapeutic potential of cannabis, psilocybin, and dimethyltryptamine (DMT), the Drug Enforcement Administration (DEA) has decided to increase production quotas for these substances. Regarding comments requesting increased production quotas for religious use of psychedelics, the agency did not directly address such requests or schedule a hearing with the DEA administrator. To date, there has been no indication that the DEA plans to reschedule marijuana as a result of this state-level decision. Nevertheless, it has been open to dialogue and consideration of different perspectives on this matter.Moreover, the DEA received comments recommending the inclusion of natural sources of psilocybin, psilocin, and mescaline when setting quotas. It is up to these organizations to strike a balance between public interest, safety, and the advancement of medical knowledge for the benefit of all.

Article Preview

To accommodate the growing demand for research into the therapeutic potential of cannabis, psilocybin, and dimethyltryptamine (DMT), the Drug Enforcement Administration (DEA) has decided to increase production quotas for these substances. This change is in response to requests from registered manufacturers who have emphasized the need for higher limits to meet the requirements of medical and scientific communities.

These revised quotas reflect not only the increasing interest in the therapeutic effects of these compounds but also recognize the progress made in research and clinical trials involving hallucinogenic substances.

Initial...

Read the full article @ Marijuana Index